|D021821||Communicable Diseases, Emerging NIH||0.71|
|D003141||Communicable Diseases NIH||0.08|
There is one clinical trial.
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19.
Description: Achievement of undetectable SARS-CoV-2 RNA by Day 5 in nasopharyngeal (NP) swabs by quantitative reverse transcription polymerase chain reaction (qPCR) after administration with EIDD-2801Measure: Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801 Time: 28 days
Description: Incidence of Serious Adverse Events in subjects receiving EIDD-2801Measure: Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS Time: 28 days
Description: Incidence of Adverse Events in subjects receiving EIDD-2801Measure: Number of Participants With any Adverse Events(AEs) as assessed by DAIDS Time: 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports